NDDs, 7 and two de novo variants in SETD1B have been reported in developmental disorders in a large cohort exome study. 8 Recently, we reported two individuals with de novo SETD1B variants who had epilepsy (one showed EMA), developmental delay, intellectual disabilities (ID), autistic behavior, and craniofacial dysmorphic features. 9 These findings suggested that de novo SETD1B variants are causative for NDDs with epilepsy.
Here, we report a new individual with a de novo SETD1B missense variant having EMA, ID, language disorder, and autism spectrum disorder (ASD). We will discuss the phenotypic features of SETD1B-associated disorders.
| METHODS
After receiving written informed consent, the genomic DNA of the patient and his parents was extracted from blood leukocytes. Genomic DNA of the patient was captured using a SureSelect Human All Exon V6 kit (Agilent Technologies) and sequenced by a NextSeq 500 (Illumina) with 150-bp paired-end reads. Exome data processing, variant calling, and variant annotation were performed as previously described. 9 Candidate variants were confirmed by Sanger sequencing. Biological parentage was confirmed by analyzing 10 microsatellite markers. Experimental protocols were approved by the Institutional Review Board of Hamamatsu University School of Medicine.
| RESULTS

| Case presentation
A Japanese boy was born to nonconsanguineous healthy parents as a second child without asphyxia at 37 weeks of gestation. His birthweight and length were 3,008 g (+0.82 standard deviation [SD] ) and 50 cm (+1.4 SD), respectively. There was no family history of NDDs. He required respirator support because of transient tachypnea of the newborn. Although his motor development was normal, his language development was markedly delayed. He spoked his first word at 2 years and 3 months old and was able to combine two words at 3 years old. At 5 years old, he was diagnosed with mild ID (intelligence quotient [IQ] 64, Tanaka-Binet Intelligence Scale). At 6 years old, his full-scale IQ (WISC-IV) was 56. He poorly interacted with others and showed hyperactive behavior. He was then diagnosed as ASD at 6 years old based on the Pervasive Developmental Disorders Autism Society Japan Rating Scale.
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At 3 years and 7 months old, he began to show myoclonic absence seizures lasting 3-5 seconds and occurring 4-5 times per day. His seizures were refractory to antiepileptic drugs including valproate, ethosuximide, levetiracetam, clobazam, and topiramate. The ketogenic diet was also tried but interrupted because he did not appreciate the importance of the treatment. At 7 years and 10 months old, interictal electroencephalogram (EEG) revealed a spike-and-slow wave complex with dominance in the frontal area ( Figure 1) . In an ictal video-EEG and polygraph (EEG and electromyogram) recording, diffuse synchronous 3-Hz spike-and-wave bursts were observed synchronized with bilateral upper limb myoclonic jerks accompanied by loss of consciousness. These findings matched the criteria of myoclonic absence seizure. At the time of this writing, his myoclonic absence seizures occur 10-20 times per day and last 30 seconds despite valproate and lamotrigine treatment.
Upon final examination at 8 years and 1 month old, his height was 124.6 cm (−0.23 SD), his weight was 28.8 kg (+0.49 SD), and his head circumference was 54.5 cm (+1.4 SD). He had no dysmorphic features. Brain MRI showed normal brain structure.
| Variant screening
Using WES, we searched for candidate variants in known epilepsy-and NDD-related genes and found a possible pathogenic variant in SETD1B (NM_001353345.1: c.386T>G, p. (Val129Gly)). Sanger sequencing confirmed that this variant occurred de novo ( Figure 1C ). It was absent in our 218 in-house Japanese control exomes and public databases including the gnomAD (http://gnomad. broad insti tute.org/) and 2KJPN (https ://ijgvd.megab ank. tohoku.ac.jp/). This variant was predicted to be deleterious by multiple in silico pathogenicity prediction tools: The CADD PHRED score was 28.3 (http://cadd.gs.washi ngton. edu/snv), the PP2_HVAR score was 0.994 (http://genet ics. bwh.harva rd.edu/pph2/), the SIFT score was 0 (http://sift. jcvi.org/), the MutationTaster score was 1.0 (http://www. mutat ionta ster.org/), and the Missense Tolerance Ratio was 0.503 (24.9th percentile <25th percentile; http://mtrviewer.mdhs.unime lb.edu.au/mtr-viewe r/). 11 The variant was considered likely pathogenic according to ACMG Standards and Guidelines (PS2, PM2, PP3). The altered residue was located at the RNA recognition motif (RRM) domain and highly evolutionarily conserved ( Figure 1D) . We also examined possible pathogenic copy number variants (CNVs) using WES data with the eXome-Hidden Markov Model (XHMM) 12 and the methods developed by Nord et al 13 ; however, no possible pathogenic CNVs were found in this case. These findings suggested that this variant is likely to be pathogenic in this case.
| DISCUSSION
To date, we found three de novo SETD1B variants in three unrelated Japanese individuals with NDDs and epilepsy. The
clinical manifestations of these individuals are summarized in Table 1 . In all cases, the developmental milestones were delayed before the onset of seizures. They started to show autistic behaviors and various degrees of ID in early childhood. However, facial dysmorphic features were seen in only one of the three individuals. Epilepsy is also common to all the three individuals. Individuals with microdeletion of 12q24.31 including SETD1B also had epilepsy in two of the four cases, 8 suggesting that epilepsy is strongly associated with SETD1B defects, although clinical features could be modified by defects in other genes located within the deletion interval. Interestingly, EMA was noted in two of the three individuals. 9,14 EMA is a rare and specific type of seizure that was accounts for 0.5%-1% of total epilepsies. 1 Although the myoclonic seizures of the remaining case were not thought to be myoclonic absences based on interictal EEG findings, evidence suggests that SETD1B may be a candidate gene for EMA.
Previous work suggested that histone H3 lysine 4 trimethylation (H3K4me3) was involved in learning and memory consolidation. 15 Animal models showed that the level of H3K4me3 increased in the CA1 region of the dorsal hippocampus during memory retrieval. 16 Moreover, it was revealed that the variants in genes constituting components of the H3K4 regulatory machinery caused rare congenital dysmorphic syndromes with NDDs involving ID, ASD, and schizophrenia. 17 These findings indicated that the dysfunction of the enzymatic activity of SETD1B may be likely to reduce H3K4me3 in the neuronal system and cause disabilities of normal learning and consolidation of memories. Meanwhile, involvement of epilepsy was variable in cases with variants in histone H3K4 methyltransferases. Our data suggest that epilepsy is strongly associated with SETD1B defects. In regulating the H3K4 trimethylation pattern in mammalian cells, WDR82 is a component of the SETD1A and SETD1B complexes that influence target selection, but is not associated with other SET1-family complexes such as KMT2A-KMT2D. 18 In addition, it has been reported that SETD1B has more robust trimethylase activities than KMT2A-KMT2D. histone methyltransferase complex that generates mono-, di-, and trimethylated histone H3 at Lys4 and has been implicated in multiple biological processes. 6 SETD1B has four evolutionarily conserved functional domains: the RRM domain, the N-SET domain, the catalytic SET domain, and the post-SET domain. The SET domain plays a principal role in catalyzing histone methylation, and loss-of-function variants in this domain may cause impairment of enzymatic activity of H3K4 methyltransferase. The RRM domain is commonly shared by the many RNA binding proteins used for interaction with RNA bases. It acts as a positive regulator of trimethylation by SET1-family methyltransferases, and dysfunction in the RRM domain may bring about inadequate trimethylation leading to an abnormal transcriptional regulation of genes. 19 Therefore, loss-of-function variants in the RRM domain may also induce dysregulation of enzymatic activity of H3K4 methyltransferase. In previous and present studies, eight de novo variants in SETD1B had been identified in individuals with neurodevelopmental or psychiatric diseases [20] [21] [22] (Table   S1 ). Four missense SETD1B variants were located in the SET domain or RRM domain, and these four variants were predicted to be deleterious by multiple in silico tools. While the p.(Thr1005Asnfs*4) is a null variant and is very likely to be pathogenic, the pathogenicity of the other missense variants located outside the domain was less significant (Table S1 ). All three patients in our work showed very similar phenotypes although their variants were located in the different domains.
The clinical details of the previous studies were not available, but both missense and protein-truncating variants may cause developmental disorders. Therefore, loss-of-function variants in the functional domains of SETD1B may induce dysregulation of enzymatic activity of H3K4 methyltransferase and have association with the etiology of neurodevelopmental disorders. However, further accumulation of additional cases will need to clarify the pathogenicity of variants and phenotype-genotype correlations. In conclusion, we described an additional case of a de novo SETD1B variant with EMA, developmental delay, ID, and ASD. This case supports the indication that SETD1B may be a causative gene for syndromic NDD with epilepsy, especially its association with EMA. However, further accumulation of cases and functional analyses are necessary for clarifying the phenotypic spectrum and the pathogenesis of SETD1B-related disorders.
